Health Care Activity
Medtronic’s PillCam Genius SB Completes First Patient Procedure for GI Diagnostics
Medtronic, PillCam Genius SB, Capsule Endoscopy, GI Diagnostics, At-Home Ingestion, Telehealth
Eli Lilly and Ro Partner to Expand Access to Affordable Zepbound Single-Dose Vials for Obesity Treatment
Eli Lilly, Ro, Zepbound, Single-dose vials, Obesity treatment, Telehealth, Affordable medication, Self-pay pharmacy
FDA Action Alert: Recent Developments on Unapproved Drugs and Prescription Drug Approvals
FDA Action Alert, Unapproved Drugs, Prescription Drug Approvals, Azurity Pharmaceuticals Inc., Bristol Myers Squibb, Ionis, Lexicon
Empowering Patients: The Key to Faster, More Impactful Research
Patient-centered care, Patient engagement, Personalized medicine, Clinical research, Healthcare outcomes, Patient empowerment
Novo Holdings Receives Unconditional EU Approval for $16.5 Billion Acquisition of Catalent
Novo Holdings, Catalent, European Commission, Acquisition, EU Approval, Pharmaceutical Services
AstraZeneca Appoints Iskra Reic as New International Operations Lead Following Investigation into China Executive
AstraZeneca, Iskra Reic, Leon Wang, China investigation, international operations lead
The Fallout of Research Misconduct: Implications for Neurodegenerative Disease Studies
Research misconduct, Neurodegenerative diseases, Eliezer Masliah, NIH investigations, Future of neurodegenerative research
Healthcare Evolution 2025: AI, IRA, and GLP-1s Redefine the Industry
AI in Healthcare, IRA Impact on Biopharma, GLP-1 Medications, Healthcare Trends 2025, Value-Based Care, Telemedicine Integration, Pharmaceutical Industry Shifts, Healthcare Technology Advancements
Gilead Sciences Surpasses Q3 Earnings and Sales Forecasts, Boosts Annual Outlook
Gilead Sciences, Q3 earnings, HIV drug sales, annual guidance, Biktarvy, Veklury, lenacapavir, HIV prevention
Bristol Myers Squibb Posts Strong Q3 Results, Boosts 2024 Guidance on Robust Sales of Legacy and New Drugs
Bristol Myers Squibb, Q3 earnings, 2024 guidance, legacy drugs, newer drugs, pharmaceutical industry, financial performance